Search

Displaying results 8171 - 8180 of 9117 in total
  1. Drug

    BS-001

    go.drugbank.com/drugs/DB17415
    Investigational

    BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).

  2. Drug

    BN‐Brachyury vaccine

    go.drugbank.com/drugs/DB17425
    Experimental

    BN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. It is composed of the [MVA-BN-brachyury-TRICOM vaccine] and the fowlpox virus(FPV)‐Brachyury booster vaccine.[A255173]

  3. Drug

    BSK02

    go.drugbank.com/drugs/DB17434
    Experimental

    BSK02 is a Sperm Protein-17 oral microparticle vaccine

  4. Drug

    BB-1701

    go.drugbank.com/drugs/DB17443
    Investigational

    BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.

  5. Drug

    F6-734

    go.drugbank.com/drugs/DB17444
    Experimental

    F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine pentaacetic acid (DTPA) (hMN-14 × m734).[A255217,A255222]

  6. Drug

    Erfonrilimab

    go.drugbank.com/drugs/DB17446
    Investigational

    Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).

  7. Drug

    MK-4830

    go.drugbank.com/drugs/DB17454
    Investigational

    MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.

  8. Drug

    TASO-001

    go.drugbank.com/drugs/DB17463
    Investigational

    TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.

  9. Drug

    KF-0210

    go.drugbank.com/drugs/DB17476
    Investigational

    KF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.

  10. Drug

    BI-836880

    go.drugbank.com/drugs/DB17484
    Investigational

    BI-836880 is a humanized bispecific nanobody that targets VEGF and Ang2.